Gritstone Oncology

53 articles about Gritstone Oncology

• Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

  7/19/2018

  Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001

• Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting

  4/12/2018

  Gritstone Oncology announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGETM (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be presented during two poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting.

• Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations

  3/19/2018

  Senior Biopharma Executive Brings More Than 25 Years of Global Pharmaceutical Production and Supply Experience Across Vaccines, Biologics and Oligonucleotides.

• Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer

  1/23/2018

  Gritstone Oncology announced today the appointment of Jean-Marc Bellemin as Executive Vice President of Finance and Chief Financial Officer, effective January 5, 2018.

• 

  Bay Area's Gritstone Oncology to Ramp Up Hiring at New Manufacturing Facility

  11/28/2017

  Gritstone Oncology is hanging a "help wanted" sign as the company looks to staff a new 43,000 square-foot manufacturing facility in Pleasanton, Calif. that will be the center of the company's immunotherapy manufacturing efforts.

• Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

  10/18/2017

  Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.

• Google Gets in on Bay Area Gritstone Oncology's $92.7 Million Series B Boost

  9/7/2017

• Gritstone Oncology Expands Scientific Advisory Board With Appointment Of Immuno-Oncology Experts James L. Gulley And Alessandro Sette

  6/1/2017

• Genentech Exec Jumps Ship to Become CMO at Gritstone Oncology

  5/5/2017

• Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., As Chief Medical Officer

  5/3/2017

• First Public Data Presented From Gritstone Oncology’s Tumor Antigen Identification Platform For Personalized Cancer Immunotherapy

  3/31/2017

• Immune Design Corporation And Gritstone Oncology Announce Clinical Collaboration For Neoantigen Cancer Immunotherapy

  5/9/2016

• Gritstone Oncology Appoints Dr. Karin Jooss As Chief Scientific Officer

  4/13/2016